The management strategy for MDS with SF3B1 mutations is similar to that of low-risk MDS in patients who are extensively treated with erythropoietin (EPO) for chronic anemia, receive regular red blood cell transfusions, and are relapsed or refractory after erythropoiesis-stimulating agent (ESA) therapy. Here, SF3B1 is linked to myelodysplastic syndrome.